Reuters logo
BRIEF-Motif Bio ‍announces positive topline results for iclaprim in revive-2 phase 3 study​
October 4, 2017 / 6:16 AM / in 2 months

BRIEF-Motif Bio ‍announces positive topline results for iclaprim in revive-2 phase 3 study​

Oct 4 (Reuters) - Motif Bio Plc

* POSITIVE TOPLINE RESULTS IN PHASE THREE STUDY

* ‍ANNOUNCES POSITIVE TOPLINE RESULTS FOR ICLAPRIM IN REVIVE-2 PHASE 3 STUDY​

* ‍ICLAPRIM WAS WELL TOLERATED IN STUDY​

* ‍NDA SUBMISSION EXPECTED IN Q1 OF 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below